Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2016', provides in depth analysis on Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) 
- The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) Overview 7
Therapeutics Development 8
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Stage of Development 8
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Therapy Area 9
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Indication 10
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Products under Development by Companies 13
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development 19
Actelion Ltd 19
C4X Discovery Holdings PLC 20
Eisai Co., Ltd. 21
Hager Biosciences, LLC 22
Heptares Therapeutics Limited 23
Merck & Co., Inc. 24
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles 25
DORA-12 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
EORA-101 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
HTL-6641 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
lemborexant - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecule to Antagonize Orexin Receptor Type 1 for Neurology - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
suvorexant - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Projects 39
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products 40
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Featured News & Press Releases 41
Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia 41
May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development 42
Feb 03, 2015: Merck's Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 43
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 43
Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 45
Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 45
Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck's Investigational Medicine for Insomnia 47
May 22, 2013: Merck Wins FDA Panel Recommendation For Insomnia Drug Suvorexant At Lower Dose 48
May 20, 2013: Merck's Experimental Insomnia Drug Safe But May Carry Troublesome Side Effects, FDA Staff Says 48
Apr 03, 2013: Merck's Insomnia Drug Suvorexant Induces Sleep With Fewer Side Effects, Preclinical Study Shows 49
Nov 28, 2012: New Drug May Offer New Approach To Treating Insomnia, Study Finds 49
Nov 08, 2012: Merck Announces FDA Acceptance Of New Drug Application For Suvorexant 50
Sep 10, 2012: Merck Announces New Phase III Data For Investigational Insomnia Medicine Suvorexant 50
Jun 13, 2012: Merck Announces New Positive Data From Two Pivotal Phase III Efficacy Trials Of Suvorexant For Treatment Of Insomnia 52
Feb 06, 2012: Merck Provides Update On Development Program For Investigational Insomnia Drug, Suvorexant 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 18
Pipeline by Actelion Ltd, H2 2016 19
Pipeline by C4X Discovery Holdings PLC, H2 2016 20
Pipeline by Eisai Co., Ltd., H2 2016 21
Pipeline by Hager Biosciences, LLC, H2 2016 22
Pipeline by Heptares Therapeutics Limited, H2 2016 23
Pipeline by Merck & Co., Inc., H2 2016 24
Dormant Projects, H2 2016 39
Discontinued Products, H2 2016 40